Moving the Needle With Checkpoint Inhibition in MCC and SCAC

Cathy Eng, MD, FACP, FASCO, highlights the significance of the FDA approval of retifanlimab for managing locally recurrent or metastatic SCAC.

Michael K. Wong, MD, PhD, FRCPC, discusses the landscape of Merkel cell carcinoma, including the role of immunotherapy and multidisciplinary treatment.

Retifanlimab demonstrated durable activity with a tolerable safety profile in patients with chemotherapy-naive MCC.